OmniAb, Inc. (NASDAQ:OABI – Get Rating) Director John L. Higgins sold 9,000 shares of OmniAb stock in a transaction that occurred on Tuesday, May 23rd. The stock was sold at an average price of $4.05, for a total value of $36,450.00. Following the transaction, the director now owns 2,462,686 shares of the company’s stock, valued at $9,973,878.30. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
OmniAb Stock Performance
Shares of NASDAQ OABI opened at $4.17 on Friday. The company has a 50 day simple moving average of $3.62 and a 200 day simple moving average of $3.60. OmniAb, Inc. has a 1 year low of $1.91 and a 1 year high of $10.50.
OmniAb (NASDAQ:OABI – Get Rating) last announced its quarterly earnings results on Thursday, March 30th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.05. The business had revenue of $35.35 million during the quarter, compared to analyst estimates of $24.73 million. As a group, research analysts expect that OmniAb, Inc. will post -0.11 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
OABI has been the subject of several research analyst reports. Cowen began coverage on shares of OmniAb in a report on Wednesday, February 22nd. They set an “outperform” rating and a $10.00 target price for the company. Cowen began coverage on OmniAb in a research report on Wednesday, February 22nd. They set an “outperform” rating and a $10.00 price objective for the company. Benchmark started coverage on OmniAb in a research report on Thursday, April 20th. They issued a “buy” rating and a $8.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of OmniAb in a research note on Friday, March 31st. Finally, Craig Hallum started coverage on shares of OmniAb in a research note on Thursday, April 13th. They issued a “buy” rating and a $10.00 price target on the stock. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, OmniAb currently has an average rating of “Buy” and a consensus target price of $10.00.
OmniAb Company Profile
OmniAb, Inc, a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates.
- Get a free copy of the StockNews.com research report on OmniAb (OABI)
- 3 Electrical Gear Makers: Hidden Gems Amid Growing Digitization
- Can ULTA’s Defensive Product Line Stand Against This Down Cycle
- A Reversal Is Brewing For Medtronic: Buying The Dip
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.